Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faropenem Medoxomil in Pediatric Acute Otitis Media
NCT00276042Phase 2Completed
- Sponsor
- Replidyne, Inc.
- Start
- Jan 2006
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of faropenem medoxomil in acute otitis media (AOM) (4 arms), sponsored by Replidyne, Inc. Primary endpoint: Bacteriologic Eradication. Started Jan 2006; status: completed.
02
Drugs
faropenem medoxomil
03
Conditions
acute otitis media (AOM)
Beyond the preview
Go deeper on NCT00276042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276042.